Recombinant Retrovirus Vector Stability and Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current replication competent retroviral vectors face challenges in maintaining stability and efficiency during infection and replication, particularly in treating cell proliferative disorders, with issues related to extra nucleotide sequences and reduced polymerase efficiency.
Innovation Solution
A recombinant replication competent retrovirus is developed, comprising a retroviral GAG protein, POL protein, envelope, and polynucleotide with specific sequences and domains, including a CMV promoter, IRES, and LTR sequences, derived from murine leukemia virus, which maintains higher replication competency and stability compared to existing vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If replication competent retroviral vectors are used for gene delivery, then transduction efficiency is improved, but stability during infection and replication deteriorates
Solution Approach 1:
The patent removes extra nucleotide sequences from the retroviral vector backbone to eliminate instability factors. By extracting only the essential elements needed for replication competency while discarding redundant sequences, the vector achieves both high transduction efficiency and improved stability during infection and replication cycles.
Solution Approach 2:
The patent optimizes the nucleotide sequence parameters of the retroviral vector by eliminating unnecessary sequences and refining the backbone structure. This parameter optimization reduces genomic complexity while maintaining replication competency, thereby improving vector stability without sacrificing transduction efficiency.
2Quantity of substance
If extra nucleotide sequences are included in the vector, then transgene capacity is improved, but polymerase efficiency deteriorates
Solution Approach 1:
The patent segments the vector genome into essential and non-essential portions, retaining only the critical nucleotide sequences required for replication and transgene expression. By dividing the genome and removing redundant segments, the vector maintains adequate transgene capacity while optimizing polymerase efficiency through streamlined sequence architecture.
Solution Approach 2:
The patent extracts and removes extra nucleotide sequences that do not contribute to essential viral functions. This extraction process eliminates polymerase inefficiencies caused by redundant sequences while preserving sufficient capacity for transgene expression, achieving an optimal balance between transgene capacity and polymerase efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant retrovirus demonstrates enhanced stability and transduction efficiency, effectively treating cell proliferative disorders by maintaining transcription activity and translational viability of encoded polypeptides, as shown in cell killing assays and therapeutic models.
Implementation Method 1
cis-acting sequences necessary for reverse transcription, packaging and integration in a target cell
Implementation Method 2
a promoter sequence at the 5' end of the retroviral polynucleotide, said promoter being suitable for expression in a mammalian cell
Implementation Method 3
a cassette comprising an internal ribosome entry site (IRES) operably linked to a heterologous polynucleotide
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.